Clinical effect of aquatop rescue cream in patients with mild or moderate exacerbation of atopic dermatitis
DOI:
https://doi.org/10.29176/2590843X.1737Keywords:
Dermatitis, Atopic, Symptom Flare Up, Probiotics, Plants, MedicinalAbstract
Introduction: Atopic dermatitis produces intense itching and eczematous lesions that worsen chronic quality of life. The dermocosmetic Aquatop rescue cream is currently available, indicated for mild and moderate conditions. The objective was to describe the clinical course of a cohort of patients with exacerbation of atopic dermatitis, who received treatment with Aquatop rescue cream for a period of fifteen days.
Methods: A retrospective descriptive study based on the clinical records of a court of patients with mild to moderate exacerbation of their atopic dermatitis. Its evolution was described using the SCORAD variable that measures the level of severity of atopic dermatitis. Additionally, the average pruritus and its maximum level in the last 24 hours were recorded. Three evaluations were carried out: baseline, seventh day and fifteenth day.
Results: The clinical data of 60 patients were recorded, with a median age of 12.5 years (IQR: 7-19.5), and 50.0% were men (30/60). The median SCORAD at admission was 29.4 points, it decreased to 14 points on the seventh day and reached 12.2 points on the fifteenth day. At the beginning of the follow-up, 65% of the cases were classified as moderate exacerbation, and this percentage was reduced on the seventh day to 13.3%, which decreased to 10% on day fifteen.
Conclusions: Aquatop rescue cream is a therapeutic alternative that has a favorable clinical effect in patients with mild and moderate exacerbations of atopic dermatitis, due to its rapid effect on the reduction of symptoms and its adequate safety profile.
Author Biographies
Angelica Monterrosa, FUCS
SIIES Consultores S.A.S.
Oscar Eduardo Mora, Fundación Universitaria de Ciencias de la Salud - FUCS.
Fundación Universitaria de Ciencias de la Salud - FUCS.
Guillermo Sánchez-Vanegas, Hospital Universitario Mayor-Mederi. Universidad del Rosario.
Hospital Universitario Mayor-Mederi. Universidad del Rosario.
María Fernanda Ordoñez, Hospital Militar Central
Hospital Militar Central
Andrés Bastidas, Clínica Imbanaco. Quiron Salud Médico
Clínica Imbanaco. Quiron Salud Médico
Natalia Velázquez, Asociación Colombiana de Dermatología Pediátrica
Asociación Colombiana de Dermatología Pediátrica
Viviana Garzón, Asociación Colombiana de Dermatología y Cirugía Dermatológica - AsoColDerma
Asociación Colombiana de Dermatología y Cirugía Dermatológica - AsoColDerma. Colegio Ibero-Latinoamericano de Dermatología - CILAD.
Ingrid Angulo, Coomeva
Colmédica MP. Coomeva MP.
Mauricio Torres, Fundación Universitaria de Ciencias de la Salud - FUCS.
Fundación Universitaria de Ciencias de la Salud - FUCS.
Lina Quiroz, Hospital Pablo Tobón Uribe
Hospital Pablo Tobón Uribe
Sylvia Yaneth Rodríguez, Megalabs Colombia S.A.S.
Megalabs Colombia S.A.S.
José Luis de la Hoz, Megalabs Colombia S.A.S.
Megalabs Colombia S.A.S.
Jhonatan Alfredo Alfonso, Megalabs Colombia S.A.S
Megalabs Colombia S.A.S
Álvaro Guillermo Vallejos-Narvaez, Megalabs Colombia S.A.S.
Megalabs Colombia S.A.S.
References
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-60. DOI: 10.1016/S0140-6736(20)31286-1
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-44. DOI: 10.1111/jdv.16892
Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. J Dermatolog Treat. 2020;31(8):801-9. DOI: 10.1080/09546634.2019.1655137
Armengot-Carbo M, Hernández-Martín Á, Torrelo A. The Role of Filaggrin in the Skin Barrier and Disease Development. Actas Dermo-Sifiliográficas (English Edition). 2015;106(2):86-95. DOI: 10.1016/j.ad.2013.10.019
Escarrer Jaume M, Guerra Perez MT. Dermatitis atópica2019; 2:[161-75 pp.]. Available from: https://www.aeped.es/sites/default/files/documentos/11_dermatitis_atopica.pdf
Woo TE, Somayaji R, Haber RM, Parsons L. Scratching the Surface: A Review of Dermatitis. Adv Skin Wound Care. 2019;32(12):542-9. DOI: 10.1097/01.ASW.0000604184.92824.43
Bagazgoitia L, Gutiérrez M, García Blesa C, Hernández Martín A, A. T. Aspectos epidemiológicos, patogénicos, clínicos y diagnósticos de la dermatitis atópica: ¿Es posible la prevención? Pediatría Atención Primaria. 2009;11:31-47.
Querol Nasarre I. Dermatitis atópica. Pediatría Atención Primaria. 2009;11:317-29.
Munera-Campos M, Carrascosa JM. Innovación en dermatitis atópica: de la patogenia a la terapéutica. Actas Dermo-Sifiliográficas. 2020;111(3):205-21. DOI: 10.1016/j.ad.2019.11.002
Avena-Woods C. Overview of Atopic Dermatitis. Supplements and Featured Publications. 2017;23(8).
Adamson AS. The Economics Burden of Atopic Dermatitis. Adv Exp Med Biol. 2017;1027:79-92. DOI: 10.1007/978-3-319-64804-0_8
Ring J, Zink A, Arents BWM, Seitz IA, Mensing U, Schielein MC, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019;33(7):1331-40. DOI: 10.1111/jdv.15634
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. DOI: 10.1542/peds.2014-1990
Navarro-López V, Ramírez-Boscá A, Ramón-Vidal D, Ruzafa-Costas B, Genovés-Martínez S, Chenoll-Cuadros E, et al. Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2018;154(1):37-43. DOI: 10.1001/jamadermatol.2017.3647
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015(7):CD009864. DOI: 10.1002/14651858.CD009864.pub2
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75. DOI: 10.1186/s12887-016-0607-9
Chia BK, Tey HL. Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis. 2015;26(3):122-32. DOI: 10.1097/DER.0000000000000118
Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415-28. DOI: 10.1111/j.1365-2133.2010.10030.x
Kirsner RS, Heffernan MP, Antaya R. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Derm Venereol. 2010;90(1):58-64. DOI: 10.2340/00015555-0748
Sendagorta Cudós E, de Lucas Laguna R. Tratamiento de la dermatitis atópica2009; XI(15):[s49-s67 pp.]. Available from: https://scielo.isciii.es/pdf/pap/v11s15/4_tratamiento_da.pdf
Ballona Chambergo R. Inhibidores de la calcineurina: una alternativa en el tratamiento inmunosupresor2003; 13(2):[121-3 pp.]. Available from: https://sisbib.unmsm.edu.pe/bvrevistas/dermatologia/v13_n2/inhibidores.htm
Kim J, Gorman J. The psychobiology of anxiety. Clinical Neuroscience Research. 2005;4(5):335-47. DOI 10.1016/j.cnr.2005.03.008
Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Consulta datos de productos [Available from: http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp.
Passeron T, Lacour JP, Fontas E, Ortonne JP. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy. 2006;61(4):431-7. DOI: 10.1111/j.1398-9995.2005.00956.x
Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child. 2005;90(9):892-7. DOI: 10.1136/adc.2004.060673
Makino T, Hamanaka M, Yamashita H, Mizukami H. Effect of bakumijiogan, an herbal formula in traditional Chinese medicine, on atopic dermatitis-like skin lesions induced by mite antigen in NC/Jic mice. Biol Pharm Bull. 2008;31(11):2108-13. DOI: 10.1248/bpb.31.2108
Mainzer C, Le Guillou M, Vyumvuhore R, Chadoutaud B, Bordes S, Closs B. Clinical Efficacy of Oligofructans from Ophiopogon japonicus in Reducing Atopic Dermatitis Flare-ups in Caucasian Patients. Acta Derm Venereol. 2019;99(10):858-64. DOI: 10.2340/00015555-3224
How to Cite
Downloads
![](https://revista.asocolderma.org.co/public/journals/1/submission_1737_1632_coverImage_es_ES.jpg)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |